CXCL17 methylation as a potential marker for papillary thyroid carcinoma
10.13315/j.cnki.cjcep.2025.05.012
- VernacularTitle:CXCL17基因甲基化作为甲状腺乳头状癌的潜在标志物
- Author:
Chenxia JIANG
1
;
Mengxia LI
;
Haixia HUANG
;
Junjie LI
;
Yifei YIN
;
Rongxi YANG
Author Information
1. 南通大学附属医院病理科,南通 226001
- Publication Type:Journal Article
- Keywords:
papillary thyroid carcinoma;
benign thyroid nodule;
CXCL17;
DNA methylation;
biomarkers
- From:
Chinese Journal of Clinical and Experimental Pathology
2025;41(5):627-633,638
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To investigate the correlation between the methylation level at CpG sites of CXCL17 and the clinicopathological parameters of papillary thyroid carcinoma(PTC).Methods samples from 186 cases of PTC and 191 cases of benign thyroid nodule(BTN)were collected.Methylation levels of CXCL17 were semi-quantitatively as-sessed using mass spectrometry.Logistic regression analysis,which adjusted for age,gender and related hormones,was conducted to evaluate the correlation between CXCL17 methylation and PTC,and calculate the odds ratios(ORs)and 95％confidence intervals(CIs).Results Hypomethylation level of CXCL17_CpG_1.2 was significantly associat-ed with PTC(OR=1.36,95％CI:1.16-1.60,P＜0.001)and early stage of PTC patients(Stage Ⅰ,OR=1.41,95％CI:1.19-1.67,P＜0.001).Gender-based hierarchical management analysis showed that decreased methyla-tion level of CXCL17_CpG_1.2 was significantly associated with female PTC patients(OR=1.39,95％CI:1.15-1.67,P＜0.001).In subgroups stratified by age(＜50 and≥50 years old),hypomethylation at CXCL17_CpG_1.2 was significantly associated with PTC,with a stronger association in the younger subgroup(＜50 years old:OR=1.42,95％CI:1.14-1.77,P＜0.01;≥ 50 years old:OR=1.30,95％CI:1.03-1.64,P＜0.05).Conclusion There was a significant difference in CXCL17 methylation levels between benign and malignant thyroid tumors.It was showed that hypomethylation of CXCL17 is closely associated with PTC,particularly in young women patient.Thus,CXCL17 methylation may serve as a biomarker for accurate differential diagnosis of thyroid nodule.
